	US 12,433,935 B2
	Producing method of mesenchymal stem cell for prevention or treatment of brain neuronal disease including ghrelin treatment and use thereof
Jong Wook Chang, Seoul (KR); and Hyeong Seop Kim, Incheon (KR)
Assigned to Samsung Life Public Welfare Foundation, Seoul (KR)
Appl. No. 17/295,385
Filed by Samsung Life Public Welfare Foundation, Seoul (KR)
PCT Filed Feb. 9, 2021, PCT No. PCT/KR2021/001737 § 371(c)(1), (2) Date May 19, 2021, PCT Pub. No. WO2021/162426, PCT Pub. Date Aug. 19, 2021.
Claims priority of application No. 10-2020-0017782 (KR), filed on Feb. 13, 2020.
Prior Publication US 2022/0339258 A1, Oct. 27, 2022
Int. Cl. A61K 38/22 (2006.01); A61K 35/28 (2015.01); A61P 25/28 (2006.01); C12N 5/0775 (2010.01)

CPC A61K 38/22 (2013.01) [A61K 35/28 (2013.01); A61P 25/28 (2018.01); C12N 5/0665 (2013.01); C12N 2501/30 (2013.01)]

2 Claims

1. A method for producing mesenchymal stem cells for treating brain neuronal diseases, the method comprising treating mesenchymal stem cells with ghrelin at a concentration of 1 nM to 100 nM for 6 to 12 hours, wherein the treatment results in the mesenchymal stem cells having an increased AgRP (Agouti related peptide) expression level compared to mesenchymal stem cells not treated with ghrelin, wherein said mesenchymal stem cells are derived by Wharton's jelly.